siRNA
| 4 min read
Rare disease approvals, multi-billion-dollar deals, and more led this week’s headlines.
| 6 min read
With the first wave of FDA-approved siRNA drugs under their belt, companies are racing to expand into new tissues and indications.
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 8 min read
Alnylam Pharmaceuticals develops therapeutics based on the RNA interference (RNAi) pathway discovered in 1998.
| 2 min read
Bioasis announces publication evaluating CNS delivery of siRNA via the company’s xB³ platform
Page 1 of 1 - 5 Total Items
